ID: ALA5269753

Max Phase: Preclinical

Molecular Formula: C21H29N3O3S

Molecular Weight: 403.55

Representations

Canonical SMILES:  COc1cc(N(C)CCO)ccc1/C=C1\C(=O)N(C2CCCCC2)C(=S)N1C

Standard InChI:  InChI=1S/C21H29N3O3S/c1-22(11-12-25)17-10-9-15(19(14-17)27-3)13-18-20(26)24(21(28)23(18)2)16-7-5-4-6-8-16/h9-10,13-14,16,25H,4-8,11-12H2,1-3H3/b18-13+

Standard InChI Key:  LIEJGXFJBCVLIW-QGOAFFKASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 403.55

Molecular Weight (Monoisotopic): 403.1930

AlogP: 2.86

#Rotatable Bonds: 6

Polar Surface Area: 56.25

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 2.03

CX LogP: 3.07

CX LogD: 3.07

Aromatic Rings: 1

Heavy Atoms: 28

QED Weighted: 0.58

Np Likeness Score: -0.92

References

1. Shim S, Jeong DU, Kim H, Kim CY, Park H, Jin Y, Kim KM, Lee HJ, Kim DH, Bae YS, Choi Y..  (2022)  Discovery of a NADPH oxidase inhibitor, (E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl)amino)benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease.,  244  [PMID:36274279] [10.1016/j.ejmech.2022.114854]

Source

Source(1):

• Scientific Literature